12 month median 2729 vs. 12062.5 unique TCR sequences, P ¼ .22). Median lymphocyte counts did not increase between 3 and 12 months in the PD group as in the U+UD group, but the proportion of CD3 + cells within lymphocytes increased in both groups. PD T cell repertoires were less clonal than U+UD samples at 3 months (1-normalized entropy: 0.14 vs. 1 Complejo Hospitalario de Navarra; 2 Biomedical Research Center of Navarra CMV reactivation after allo-SCT is usually monitored by CMV-PCR. We present the results of a pilot study looking at the additional use of Multimers for monitoring CMV-specific CD8+ T-cells at different intervals after allo-SCT.
1 Complejo Hospitalario de Navarra; 2 Biomedical Research Center of Navarra CMV reactivation after allo-SCT is usually monitored by CMV-PCR. We present the results of a pilot study looking at the additional use of Multimers for monitoring CMV-specific CD8+ T-cells at different intervals after allo-SCT.
10 patients (4 males) that underwent allo-SCT from HLAidentical siblings (n¼4) or HLA-matched unrelated (n¼6) donors between May 2010 and May 2012 were enrolled. The diagnosis was acute leukemia (n¼6), lymphoproliferative disorders (n¼2) and myelodysplastic syndromes (n¼2). All patients and 8 donors were CMV seropositive. All patients were positive for the HLA-A*0201 allele. Pentamers (Proimmune, UK) and Streptamers (Gottingen GmbH, Germany) were directed against the epitope NLVPMVATV of the pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] protein of CMV in the context of HLA-A*0201. Samples were obtained from engraftment at 30-day intervals until day +180 and 2-monthly thereafter.
The median follow-up was 12.6 (4-21) months after SCT. Engraftment occurred in all patients at a median of 21.2 (15-27) days. Acute GVHD was diagnosed in 4 patients at a median of 63.3 (25-92) days. One patient developed acute GVHD following infusion of donor lymphocytes for the treatment of mixed chimerism on day +323.
Three patterns were observed. In 2 patients no CMVspecific CD8+ T-cells could be detected after SCT despite several episodes of CMV-PCR reactivation requiring prolonged antiviral treatment. In 5 patients CMV-PCR reactivation triggered a rapid increase of CMV-specific CD8+ T-cells (median 112.2 x 10 5 /L, range 1.3-279.7 x 10 5 /L). However, the CMV-PCR became immediately negative and antiviral treatment was stopped in all reactivations within 2 weeks. Subsequent CMV-PCR reactivations also lasted under 2 weeks in this group. Finally, 3 patients showed an early immune reconstitution with CMV-specific CD8+ T-cells detected (median 1.3 x 10 5 /L, range 0.3-2.3 x 10 5 /L) at a median of 21 (17-33) days post-SCT. No CMV-PCR reactivation was observed in this group. We conclude that monitoring CMV-specific T-cell immunity after allo-SCT in combination with CMV-PCR may be able to distinguish patients at higher risk of CMV reactivation and in need of prolonged antiviral therapy. Patients with CMV-specific CD8+ T-cells detectable at the time of CMV-PCR reactivation may only need a short course of antiviral therapy, while those with early and persistent CMV-specific CD8+ T-cells may be at a very low risk of developing CMV disease in the long-term. 5 cells/ml). There were no significant differences between the two groups with respect to age, sex, disease or donor source, p¼0.7, 0.5, 1 and 0.07 respectively. Fours years after HSCT, Overall Survival (OS) was significantly higher for patients in the elevated group compared to the patients in the low/normal group, 93% and 60%, respectively, p¼0.0173. Survival without relapse or graft failure, Event Free Survival (EFS), was significantly higher in the elevated group compared to the low/normal group, 85.7% and 58.0%, respectively. Since T cell reconstitution following Background: CBT recipients may respond to post-transplant vaccines differently than other transplant groups due to the lack of transfer of donor immunity. Methods: We analyzed vaccine responses in 48 CBT recipients transplanted at our center from 2005-2010 for the treatment of hematologic malignancies with myeloablative or non-myeloablative conditioning. GHVD ppx included a calcineurin-inhibitor and MMF. All patients received double unit CB grafts and no pt received ATG. Vaccination criteria included CD4+ cell count > 200 cells/ul and IgG level > 500 mg/dl at > 6 weeks following the last IVIG dose. Results: Forty-eight of 69 (70%) eligible pts alive & diseasefree @ 12 months post-HCT were vaccinated. Vaccinated patients engrafted with 6/6 (n ¼ 2), 5/6 (n ¼ 26), or 4/6 (n ¼ 20) HLA-matched units. Twelve pts received rituximab (median 4 doses) as planned peri-transplant therapy for Bcell malignancies (n ¼ 6), EBV viremia/ lymphoma (n ¼ 3), autoimmune hemolysis (n ¼ 1), pure red cell aplasia (n ¼ 1), or recurrent disease (n¼1). Prior to immunization, 13 patients had no acute or chronic GVHD whereas 35 had prior grade II-IV acute and/or chronic GHVD. Overall, the median time to vaccination was 16.9 months post-CBT; 18.9 months in pts who received rituximab; 15.23 months in those who did not (P ¼ .056). Pre-vaccination titers obtained at a median of 1 yr demonstrated that > 85% of patients lacked protection against pneumococcus, H. flu, and pertussis and > 50% lacked immunity against tetanus, measles, & mumps. Seroconversion or > 3-fold rise in titer was observed in > 60% of patients in response to tetanus, diphtheria, H. flu, polio and pneumococcal (PCV7 or PCV13) vaccines. Following 3 doses of rHBV vaccine, 52% pt seroconverted. Only 2/35 recipients of a single Tdap developed protective pertussis titers; 0/8 pts responded to a single protein-conjugated meninogoccal vaccine. To date, 20 pts including 9 adults have received an MMR at a median of 2.3 years post-CBT. 8 pts received the live attenuated varicella vaccine. To date, seroconversion following measles, mumps, & rubella vaccine occurred in 56%, 41% & 93% of pts, respectively and 5 evaluable pts seroconverted after 1 (n¼3) or 2 doses of Varivax (n ¼ 2). Survival in vaccinated patients is 100%. No serious reactions to any vaccine occurred. Conclusion: CBT recipients, including adults & those with prior GVHD or rituximab therapy, are capable of responding to tetanus, diphtheria, H. flu, polio & PCV7 or PCV13 similar to other transplant groups. The sub-optimal response to pathogens associated with outbreaks in the community (Hepatitis B, Pertussis, meningococcus, measles, mumps, varicella) highlight the need to obtain pre-& post-vaccine titers to document response, and the need to define the optimal vaccination regimen in this population. The rate of immune reconstitution (IR) is directly correlated with the number of hematopoietic stem cells (HSC) infused and is particularly delayed in patients undergoing cord blood transplantation (CBT) secondary to the limited numbers of HSC. Thus, methods to increase the number of cord blood (CB) progenitors have the potential to accelerate IR after CBT. Natural killer (NK) cells play a crucial role in early IR after HCT because they are the first lymphocyte subset to recover after transplant. CB NK cells have been reported to have incomplete maturation and require activation for effective function. Here, we report a clinically relevant method for ex vivo expansion of NK cells isolated from CB without the use of a stromal layer. Our group has demonstrated that CB NK cells cultured in the presence of IL-2 and IL-15 results in a multi-log increase in the number of precursors that have a significant increase in cytotoxicity against several target cancer cell lines. After 21 days in culture, there is a 1.848 AE 0.341 log fold increase in the number of CD3-CD56+ NK cells (range, 0.420 to 3.108) (P < .001, N¼9). After culture, we also found a significant 2.612 AE 0.310 log fold increase (range, 0.979 to 3.622) (P < .001, N¼9) in the number of CD3+CD56+ NKT cells. Evaluation of cytotoxicity against K562 cells, a chronic myelogenous leukemia, showed there was also a significant increase in cytolytic function at days 14 (31.52 AE 8.317% target cell lysis, P < .01, N¼8) and 21 (44.22 AE 9.866% target cell lysis, P < .01, N¼8) in culture when compared to day of isolation; similar results were seen using Jurkat cells, an acute T-cell lymphoblastic leukemia (T-ALL). Evaluation of NK cell resistant cells lines was also tested. While we found an increase in cytotoxicity toward the myeloid lymphoid leukemia cell line (MLL), MV411, after culture, the RS411 (MLL/ ALL) and HDLM2 (Hodgkin's lymphoma) cell lines remained resistant to cytolytic killing (N¼3). Currently, we are investigating the NK cell population(s) responsible for the cytotoxic killing and the corresponding killer cell Ig-like receptor (KIR) ligand/adhesion molecule(s) that may be responsible for function. We hypothesize that using methods to increase the number of CB NK cells have the potential to prevent early relapse, infections and graft versus host disease, as well as facilitate engraftment when administered following CBT.
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